New Results
No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic
Julia Schwaiger, Michael Karbiener, Claudia Aberham, View ORCID ProfileMaria R. Farcet, Thomas R. Kreil
doi: https://doi.org/10.1101/2020.07.30.228213
Julia Schwaiger
1Global Pathogen Safety, Baxter AG, now part of the Takeda group of companies, 1221 Vienna, Austria
Michael Karbiener
1Global Pathogen Safety, Baxter AG, now part of the Takeda group of companies, 1221 Vienna, Austria
Claudia Aberham
2BioLife, Baxter AG, now part of the Takeda group of companies, 1221 Vienna, Austria
Maria R. Farcet
1Global Pathogen Safety, Baxter AG, now part of the Takeda group of companies, 1221 Vienna, Austria
Thomas R. Kreil
1Global Pathogen Safety, Baxter AG, now part of the Takeda group of companies, 1221 Vienna, Austria
Article usage
Posted July 30, 2020.
No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic
Julia Schwaiger, Michael Karbiener, Claudia Aberham, Maria R. Farcet, Thomas R. Kreil
bioRxiv 2020.07.30.228213; doi: https://doi.org/10.1101/2020.07.30.228213
Subject Area
Subject Areas
- Biochemistry (11703)
- Bioengineering (8722)
- Bioinformatics (29127)
- Biophysics (14932)
- Cancer Biology (12048)
- Cell Biology (17359)
- Clinical Trials (138)
- Developmental Biology (9406)
- Ecology (14143)
- Epidemiology (2067)
- Evolutionary Biology (18268)
- Genetics (12220)
- Genomics (16766)
- Immunology (11841)
- Microbiology (28005)
- Molecular Biology (11552)
- Neuroscience (60808)
- Paleontology (450)
- Pathology (1864)
- Pharmacology and Toxicology (3231)
- Physiology (4939)
- Plant Biology (10384)
- Synthetic Biology (2877)
- Systems Biology (7333)
- Zoology (1642)